|Table of Contents|

The mechanism on the effect of lenalidomide on activity change of diffuse large B-cell lymphoma cells after overexpression of the TNFAIP3/A20 gene

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1429-1434
Research Field:
Publishing date:

Info

Title:
The mechanism on the effect of lenalidomide on activity change of diffuse large B-cell lymphoma cells after overexpression of the TNFAIP3/A20 gene
Author(s):
XU Dan; XU Ruihuan; YANG Wenxiu
Department of Pathology,the Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550001,China.
Keywords:
lymphoma; lenalidomide; overexpression; TNFAIP3/A20; MYD88
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2024.08.010
Abstract:
Objective:The diffuse large B-cell lymphoma (DLBCL) cell line OCI-LY3 was treated with lenalidomide after overexpression of the TNFAIP3/A20 gene,and the changes of the cell line and its relationship with the expression of RNF138,MYD88 and p65 were detected,so as to explore the possible new targets to enhance the efficacy of lenalidomide in the treatment of DLBCL.Methods:Sanger method detected the MYD88 mutation of DLBCL cell line.CCK-8 method was used to determine the effect of lenalidomide on the proliferation activity of OCI-LY3 cells,and to screen cell IC50 and the optimal drug treatment time.By preparing TNFAIP3/A20 overexpression plasmid and lentivirus,OCI-LY3 cells were transfected with them to obtain a highly expressed stable cell line OCI-LY3-A20.Lenalidomide (367 μmol/L) treated OCI-LY3-A20 cell line.CCK-8 detected the changes of cell proliferation activity before and after treatment,and Western blot detected the expression changes of NFAIP3/A20,p65,RNF138,MYD88 proteins.Results:The treatment of OCI-LY3-A20 with lenalidomide caused a decrease in the expression of TNFAIP3/A20 protein in the cells.The addition of lenalidomide to OCI-LY3-A20 was further examined for the proliferative activity,and the proliferative activity was decreased by the addition of lenalidomide to OCI-LY3-A20 compared with OCI-LY3-MCS (negative control virus group).OCI-LY3-A20-Len (with lenalidomide) showed reduced proliferative activity compared to OCI-LY3-A20-NC (without lenalidomide) and OCI-LY3-MCS-Len.Comparing the protein expression levels of cultured cells in OCI-LY3-MCS-NC group,OCI-LY3-MCS-Len group,OCI-LY3-A20-NC group and OCI-LY3-A20-Len group,the results showed that TNFAIP3/A20,RNF138 and MYD88 protein expression were related.They may be important target molecules affecting the proliferation activity of OCI-LY3 cells,and have potential therapeutic value in clinical practice.Conclusion:NF-κB inhibition is not the main mechanism for the action of lenalidomide,but TNFAIP3/A20 may be an important target molecule for the action of lenalidomide,and RNF138 and MYD88 proteins are involved in it,which is a potential therapeutic target and has important clinical diagnostic and therapeutic value.

References:

［1］LIU J,MI R,CHEN L,et al.Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma:a meta-analysis of randomized controlled trials［J］.Clinical and Experimental Medicine,2022,136(Supplement 1):13-14.
[2] CAZZOLA M.Introduction to a review series:the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues［J］.Blood,2016,127(20):2375-2390.
[3] LENZ G,STAUDT LM.Aggressive lymphomas［J］.N Engl J Med,2010,362(15):1417-1429.
[4] HARRINGTON F,GREENSLADE M,TALAULIKAR D,et al.Genomic characterisation of diffuse large B-cell lymphoma［J］.Pathology,2021,53(3):367-376.
[5] HUET O,LAEMMEL E,FU Y,et al.Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor α［J］.Shock,2013,39(1):83-88.
[6] 王玲玲,杨文秀,李逸,等.TNFAIP3 siRNA对弥漫大B细胞淋巴瘤 OCI-LY1 细胞NF-κB活性及增殖的影响［J］.临床与实验病理学杂志,2016,32(4):405-412. WANG LL,YANG WX,LI Y,et al.Effects of TNFAIP3 siRNA on NF-κB activity and proliferation of diffuse large B-cell lymphoma OCI-LY1 cells［J］.Journal of Clinical and Experimental Pathology,2016,32(4):405-412.
[7] GUO T,ZHANG Y,QU X,et al.miR-200a enhances TRAIL-induced apoptosis in gastric cancer cells by targeting A20［J］.Cell Biol Int,2018,42(5):506-514.
[8] IORGA A,DONOVAN K,SHOJAIE L,et al.Interaction of RIPK1 and A20 modulates MAPK signaling in murine acetaminophen toxicity［J］.J Biol Chem,2021,296:100300.
[9] ISMAIL IH,GAGNEJ P,GENOIS MM,et al.The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice［J］.Nat Cell Biol,2015,17(11):1446-1457.
[10] YU X,LI W,DENG Q,et al.MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis［J］.Blood,2021,137(12):1615-1627.
[11] RAMCHANDREN R,JOHNSON P,GHOSH N,et al.The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL:A multicentre,non-randomised,open-label phase 2 study［J］.EClinicalMedicine,2023,56:101779.
[12] KATO M,SANADA M,KATO I,et al.Frequent inactivation of A20 through gene mutation in B-cell lymphomas［J］.Rinsho Ketsueki,2011,52(6):313-319.
[13] PAIK JH,GO H,NAM SJ,et al.Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma:an analysis according to immunohistochemical subgroups and rituximab treatment［J］.Leuk Lymphoma,2013,54(9):1934-1941.
[14] MONCRIEFFE MC,BOLLSCHWEILER D,LI B,et al.MyD88 death-domain oligomerization determines myddosome architecture:implications for Toll-like receptor signaling［J］.Structure,2020,28(3):281-289.
[15] 黄燕,章玉英,钟赟,等.弥漫大B细胞淋巴瘤不同免疫学分型的预后比较［J］.江西医药,2018,53(08):788-791，817. HUANG Y,ZHANG YY,ZHONG Y,et al.Prognosis comparison of different immunological types of diffuse large B-cell lymphoma［J］.Jiangxi Medicine,2018,53(08):788-791，817.
[16] 柴晓菲,宋魏,孙淼淼,等.生发中心与非生发中心型弥漫大B细胞淋巴瘤的临床病理因素分析［J］.中国实用医药,2016,11(20):20-21. CHAI XF,SONG　W,SUN　MM,et al.Analysis of clinicopathological factors in germinal center and non-germinal center type diffuse large B-cell lymphoma［J］.Chinese Practical Medicine,2016,11(20):20-21.
[17] 王平,杨文秀,周杰,等.弥漫大B细胞淋巴瘤中NF-κB/P65、PD-1、PD-L1 表达相关性研究及其蛋白表达的临床意义［J］.中国癌症杂志,2020,30(5):375-382. WANG P,YANG WX,ZHOU J,et al.Correlation between the expression of NF-κB/P65,PD-1 and PD-L1 in diffuse large B-cell lymphoma and its clinical significance［J］.Chinese Journal of Cancer,2020,30(5):375-382.
[18] DIMOPOUL K,SOGAARD HELBO A,FIBIGER H,et al.Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myelomacells to IMiDs in a cereblon-independent manner［J］.Mol Oncol,2018,12(2):180-195.
[19] MOONEY EC,SAHINGUR SE.The ubiquitin system and A20:Implications in health and disease［J］.J Dent Res,2021,100(1):10-20.
[20] SOLOMON LA,BATISTA CR,DEKOTER RP.Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB［J］.Exp Hematol,2017,56:46-57.

Memo

Memo:
贵州省科技计划项目（编号：黔科合支撑［2020］4Y147号）;贵州省贵阳市科技计划项目（编号:筑科合同(2019)9-1-6号）
Last Update: 1900-01-01